Meropenem Accordpharma (Meropenem Anhydrous)

Meropenem is a broad‑spectrum carbapenem used to treat severe infections caused by Gram‑negative and Gram‑positive bacteria.

• Complicated intra‑abdominal infections: provides bactericidal activity to resolve infection.
• Complicated urinary tract infections: eliminates resistant uropathogens and restores urinary sterility.
• Hospital‑acquired pneumonia: achieves rapid bacterial clearance in ventilated patients.
• Ventilator‑associated pneumonia: targets multidrug‑resistant organisms in the lower respiratory tract.
• Meningitis: penetrates the cerebrospinal fluid to eradicate causative bacteria.
• Sepsis: delivers systemic bactericidal effect to control bloodstream infection.

• Meropenem binds with high affinity to penicillin‑binding proteins (PBPs) on bacterial cell walls, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial cell death. Its broad spectrum reflects strong activity against many Gram‑negative, Gram‑positive and anaerobic organisms, including many resistant strains.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Vomiting: occasional emesis after infusion.
• Headache: transient headache during or after dosing.
• Rash: mild erythematous skin reactions.
• Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or CNS disorders.
• Anaphylaxis: acute hypersensitivity requiring immediate intervention.
• Clostridioides difficile infection: severe colitis secondary to gut flora disruption.
• Severe neutropenia: marked reduction in white blood cells.
• Renal toxicity: acute kidney injury in susceptible individuals.
• Hypersensitivity reactions: including Stevens‑Johnson syndrome.

Meropenem should be used with careful clinical assessment and monitoring.

• Assess renal function: adjust dose in patients with impaired clearance.
• Monitor for seizures: avoid in patients with a history of epilepsy or CNS disease.
• Review antibiotic susceptibility: use only when the pathogen is proven or highly suspected to be susceptible.
• Observe for allergic reactions: discontinue if signs of anaphylaxis appear.
• Evaluate hepatic status: monitor liver enzymes during prolonged therapy.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with several drugs that affect its efficacy or safety.

Major Interactions (Avoid)

• Valproic acid: carbapenems reduce serum valproate levels, increasing seizure risk.
• Probenecid: may increase meropenem plasma concentrations, heightening toxicity.
• Aminoglycosides: combined nephrotoxic potential warrants avoidance.

Moderate Interactions (Monitor Closely)

• Diuretics: may exacerbate renal impairment, requiring dose adjustment.
• Warfarin: occasional alteration of INR, necessitating closer coagulation monitoring.
• Oral contraceptives: possible reduction in hormonal efficacy, advise alternative contraception.